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ABSTRACT
Neuromyelitis optica spectrum disorders (NMOSD) are inflammatory demyelinating diseases of the central nervous system 
(CNS) that cause optic neuritis, transverse myelitis, and some other CNS syndromes. 
Recently, diagnosis and understanding of these diseases has been markedly enhanced by the discovery that serum autoantibodies 
that target aquaporin-4 (AQP4) are strongly associated with the disease. This spectrum includes also a potential subset of patients 
with a phenotype of NMOSD who have anti-myelin oligodendrocyte glycoprotein (MOG) antibody. Although steroids and immu-
nosuppressive drugs have been widely used for NMOSD treatment, until recently there was no approved therapy for these dise-
ases. With improved understanding of the pathophysiology of NMOSD, numerous new therapeutic strategies have recently been 
evaluated. The results of these studies, involving monoclonal antibodies (mAbs) inhibiting terminal complement protein cleavage 
interfering with interleukin-6 receptor (IL-6 R) signaling and depleting CD19-positive B cells, have been published in recent months. 
All of these new therapeutics have shown a high degree of efficacy in diminishing NMOSD activity and inhibiting disability progression. 
At the same time, all these mAbs have demonstrated favorable safety and tolerability profiles, with a limited rate of adverse events. 
The first of these new drugs, eculizumab, have been approved in USA and Europe for NMOSD treatment within the last couple of 
months and it is expected that the other novel, effective and safe treatments for NMOSD will be approved in the near future. 
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Introduction
Neuromyelitis optica spectrum disorders (NMOSD) are 
autoimmune inflammatory disorders of the central nervous 
system (CNS) characterised by bilateral or rapidly sequential 
optic neuritis and/or transverse myelitis. Other suggestive 
presentations include episodes of brainstem symptoms, in 
particular area postrema clinical syndrome. The disease can 
result in severe muscle weakness and paralysis, loss of vision, 
sensory loss, bladder dysfunction, neuropathic pain, and in 
the most severe cases respiratory failure [1]. The prevalence of 
NMOSD in Caucasians is relatively low at 0.5–10 per 100,000, 
but severe and frequently rapid impairment observed in pa-
tients can lead to an unfavourable prognosis, including death. 
The mechanism of NMOSD is associated with the presence 
in the serum of patients’ IgG1 antibodies against aquapo-
rin-4 (AQP4 Ab), the major water channel present within the 
CNS specifically on astrocyte endfeets at the blood-brain-
-barrier (BBB) [2]. This antibody can be found in more than
80% of patients. The discovery of AQP4 Ab has contributed 
significantly to our understanding of the pathology of NMOSD, 
also allowing for a much more precise diagnosis. AQP4 Ab 
appears to have a pathogenic role in the mechanism of NMOSD 
[3]. Recombinant AQP4 Ab after passive transfer in rats has 
induced NMOSD-specific immunopathology [4]. Serum 
AQP4 Ab titers have been shown to correlate with clinical at-
tacks and with the extent of spinal cord lesions on MRI [5, 6]. 
In addition, serum AQP4 Ab titers have been shown to drop 
after immunosuppressive treatment, and to remain low during 
remissions [7]. This antibody, produced by T-helper dependent 
B cells from the peripheral immune compartment, crosses 
the blood-brain-barrier (BBB) and interacts with AQP4 on 
astrocyte endfeet leading to astrocyte oedema and dysfunction. 
Subsequent inflammation involves complement activation, 
increased BBB permeability, and a massive influx of neutrophils 
and eosinophils [8]. Thus, inflammatory lesions in NMOSD are 
clearly different from CNS inflammation in multiple sclerosis 
(MS), where T and B cells constitute the majority of invading 
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cells. These findings, demonstrating significant mechanistic 
differences between MS and NMOSD, have allowed for a de-
finitive separation of these two clinical entities. 
More recently, another antigen was found to be associated 
with AQP4 seronegative NMOSD. Antibodies against myelin 
oligodendrocyte glycoprotein (MOG) were detected in 4–11% 
of seronegative patients [9]. Unlike AQP4 Ab, anti-MOG Ab did 
not induce astrocytic pathology. It was found that anti-MOG 
Ab led to demyelination with limited immune cell infiltration 
[10].  Anti-MOG Ab almost never co-exists with AQP4 Ab and 
occurs much more frequently in children than in adult patients. 
Despite the discovery of AQP4 Ab and anti-MOG Ab, there 
are still patients who meet the clinical diagnostic criteria of 
NMOSD, but in whose sera the two Abs cannot be detected. 
The prerequisite of a NMOSD diagnosis requires the presence 
of optic nerve and spinal cord symptoms [11]. The current 
2015 International Consensus Diagnostic Criteria for NMOSD 
are stratified according to the presence of AQP4 Ab. For se-
ropositive patients, they require the presence of at least one 
of the core manifestations, whereas for seronegative patients 
two manifestations including optic neuritis, myelitis or area 
postrema syndrome are required (Tab. 1). Recently, prelimi-
nary results have suggested the role of antibodies against glial 
fibrillary acidic protein (GFAP) in seronegative NMOSD [12]. 
Current treatment of NMOSD
Until recently, there was no approved treatment for NMOSD, 
and patients were restricted to off-label therapies bringing un-
certain benefits. Based on its clinical course, NMOSD therapy 
can be divided into relapse treatment and preventive treatment. 
Relapse treatment
For relapse, patients are usually treated with pulsed 
steroid therapy. Methylprednisolone at a dose of 1g is given 
intravenously (IV) for 3–5 days but therapy can be extended 
in a very severe relapse [13]. Relapses that respond poorly 
to methylprednisolone can be treated with plasma exchange 
(PLEX), usually 5–7 procedures every other day. PLEX can also 
be used as a first line therapy for NMOSD relapse [14]. Since 
the progression of disability in NMOSD is mainly driven by 
relapses, it is critically important that NMOSD relapse is trea-
ted as early as possible and with the most effective procedure. 
Shortly after steroid pulsed therapy or PLEX, patients 
usually are started with immunosuppressive therapies. To 
protect patients from disease progression before the immuno-
suppressive drugs start to work, prednisone or prednisolone 
can be given orally for up to six months. Relapses in NMOSD 
dependent on anti-MOG Ab usually respond better to steroid 
treatment than in AQP4 dependent disease [15]. Limited data 
indicates that intravenous immunoglobulins (IvIg) might 
show a benefit in NMOSD relapse treatment. In one study, 
the effectiveness of IvIg in the treatment of acute relapses in 
NMOSD was assessed in a retrospective review of 10 patients 
unresponsive to treatment with steroids with or without PLEX 
[16]. Improvement was noted in five of 11 (45.5%) relapses, 
and the remaining relapses had no further worsening. The 
study concluded that IvIg may have a role in treating acute 
NMOSD relapses.
Immunosuppressive treatment
Based on the autoimmune mechanism of NMOSD invol-
ving the production of auto-antibodies against AQP4 and 
MOG, several immunosuppressive agents have been tested 
in this disease over the past 30 years. Unfortunately, on most 
occasions the studies only involved a small number of patients 
and were designed as open label trials. None of these drugs 
have been formally approved for NMOSD treatment.
Traditionally, Azathioprine (AZT) was widely used as 
a first line NMOSD treatment. AZT was recommended as 
Table 1. IPND 2015 diagnostic criteria for NMOSD
NMOSD with AQP4-Ab
At least one core clinical characteristic plus positive test for AQP4-IgG using best available detection method*
Exclusion of alternative diagnoses
NMOSD without AQP4-Ab
At least two core clinical characteristics occurring as a result of one or more clinical attacks and meeting all of the following requirements:
1. At least one core clinical characteristic must be optic neuritis, acute myelitis with LETM, or area postrema syndrome.
2. Dissemination in space (two or more different core clinical characteristics).
3. Additional MRI requirements, as applicable.
4. Negative tests for AQP4-IgG using best available detection method* or testing unavailable.
5. Exclusion of alternative diagnoses.
Core clinical characteristics: Optic neuritis; acute myelitis; area postrema syndrome (hiccups, nausea and vomiting); acute brainstem syndrome; 
symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions; symptomatic cerebral syndrome with 
NMOSD-typical brain lesions.
*AQP4-IgG serology: cell-based assay is strongly recommended
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a first line preventive treatment by the EFNS panel on guide-
lines on diagnosis and management of NMO [17]. Several 
small studies have tested the efficacy of AZT alone, or in com-
bination with steroids [18]. Some of these studies showed an 
approximately 70% reduction in the  NMOSD relapse rate and 
reduced disability after several years of treatment. In a large 
retrospective review of the medical records of 103 AQP-4 an-
tibody-positive NMOSD patients, 89% (n = 92) had reduced 
their median annualised relapse rates from 1.5 (IQR 0.6–4.0) 
to 0 (IQR 0–0.27, p < 0.00005) during treatment. Sixty-one 
per cent (n = 63) remained relapse-free at a median follow-up 
of 18 months. Neurological function improved or stabilised 
in 78%. However, the discontinuation rate was 47%, reflecting 
the poor tolerability of this drug [19]. 
The other problem with AZT treatment in NMOSD is the 
delayed mechanism of action of this drug. AZT on average 
requires 3–6 months to demonstrate its effect on the immune 
system. Mitoxantrone [20], cyclophosphamide [21] and some 
other immunosuppressive treatments including methotrexate 
have demonstrated beneficial effects in NMOSD only in case 
reports and only in a limited number of patients. In addition, 
safety profiles of these drugs reduce the enthusiasm for their 
use in NMOSD. Little more data is available regarding My-
cophenolate Mofetil (MMF). In a prospective study including 
67 NMOSD seropositive and seronegative patients, MMF redu-
ced the annual relapse rate by 49% and stabilised EDSS in 80% 
of patients within a 24 month observation period. There was 
no difference between seropositive and seronegative patients 
[22]. Several retrospective studies have assessed the efficacy of 
MMF in AQP4- and MOG- seropositive and double negative 
patients. In one of these studies [23], the median post-MMF 
annualised relapse rate was significantly lower than the pre-
-MMF annualised relapse rate (0.0 vs 1.5; p < 0.001). EDSS
scores also significantly decreased after MMF treatment (3.0 vs
2.5; p = 0.005). Thirty-five patients (60%) were relapse-free with 
a median treatment duration of 20 months, and EDSS scores
were stabilised or improved in 53 patients (91%). In a similar
way to AZT, MMF requires an extended period of time to de-
monstrate its effect on the immune system, and a substantial
number of patients discontinued treatment due to side effects. 
Intravenous immunoglobulins 
In recent years, intravenous immunoglobulins (IvIg), 
which have been proven to be effective in some other antibody-
-mediated autoimmune conditions including inflammatory
demyelinating polyneuropathies [24], have attracted signifi-
cant attention in terms of NMOSD treatment. IvIg have been
shown to induce diminished activity on membrane-damaging 
components of the complement system, B cell activating
factor (BAFF), and several other immune mechanisms inclu-
ding interference with antigen recognition, downregulation
of cytokine secretion, adhesion molecules expression, and
suppression of T-cell activation relevant to NMOSD [25].
Although popular views and practical experience are strong
advocates for the use of IvIg in NMOSD, there is relatively 
little evidence to support these conclusions. 
The first study to look into the role of IvIg treatment in 
NMOSD included eight patients [26]. Five experienced re-
lapsing optic neuritis with or without myelitis, and the rema-
ining three had relapsing longitudinal extensive transverse my-
elitis (LETM). After a total of 83 infusions (4–21 per patient) 
and a mean follow-up duration of 19.3 months (6–39 months), 
it was observed that the mean relapse rate had decreased from 
1.8 in the 12 months  pre-IvIg therapy to 0.006 during follow-
-up (p = 0.0001), while the mean EDSS score had declined from 
3.3 ± 1.3 to 2.6 ± 1.5 (p = 0.04). In another study [27], the use 
of IvIg was evaluated in preventing relapses in patients with
NMOSD. Six NMOSD patients who were treated with an IvIg 
induction dose followed by infusions every 2-3 months were
retrospectively analysed. ARR and EDSS pre- and post-IvIg
were recorded. The median number of relapses and the median 
ARR were significantly reduced (8.0 to 1.0 and 0.75 to 0.15; p < 
0.05) during IvIg treatment. EDSS remained the same during 
four years of treatment.
Cell depletion therapy
The discovery of a pathological role of autoantibodies aga-
inst AQP4 and MOG in NMOSD has prompted the application 
of B cell depletion therapy which might help to eliminate an-
tibody-producing cells and improve treatment of this disease. 
Rituximab (RTX), a chimeric monoclonal antibody against 
CD20, a pan-B cell surface marker, has been tested in NMOSD 
in several small or medium-sized open labelled studies [28, 
29]. RTX very efficiently depleted B cells over a duration of 
6–9 months. Importantly, the cells from early stages of B cell 
lineage development and plasma cells were preserved, securing 
immune homeostasis during RTX treatment. 
Most of the RTX studies have shown its profound be-
neficial effect on ARR and on stabilisation and reduction of 
disability measured with EDSS. Some of these studies have 
even shown complete suppression of relapses over a  2–3 year 
period. A recently published meta-analysis analysed 26 studies, 
in which differences in the ARR ratio and EDSS score before 
and after RTX therapy were used as the main efficacy measures 
[30]. This meta-analysis involved 577 patients. Antibodies 
against aquaporin-4 were present in 435 (75.39%) patients. The 
findings suggested diminished mean ARR ratio after rituximab 
therapy by 1.56 (95% CI, -1.82 to -1.29). No significant corre-
lation was detected between the outcome of ARR ratio change 
and the following variables: age at onset, duration of disease, 
follow-up time, dose of infusion or  AQP4-IgG serostatus. The 
findings of this meta-analysis disclosed also a reduction in the 
mean EDSS score by -1.16 (95% CI, -1.36 to -0.96) during RTX 
treatment. A total of 330 out of 528 patients (62.9%) achieved 
relapse-free status. RTX showed acceptable tolerance, and 
there were no serious safety issues in NMOSD patients treated 
with RTX. All of these findings have  led to increased off label 
use of RTX in NMOSD in recent years.
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Figure 1. Emerging treatments of NMOSD
Novel emerging treatments of NMOSD
Progress in the understanding of NMOSD pathologic 
mechanisms has led to unprecedented attempts to intensify 
research into the development of new therapies in this disease 
in recent years. New therapeutic strategies have emerged which 
involve targeting novel molecules believed to be operating 
in the pathomechanism of NMOSD. These new strategies 
include the  prevention of complement activation, interfering 
with IL6 receptor (IL6-R) signalling, and the depletion of 
AQP-4 and MOG antibodies producing cells (Fig. 1). More 
importantly, these new strategies were tested in studies de-
signed as double blinded, randomised and controlled phase 
2 and 3 trials. Within the last few months, very encouraging 
results of these studies have become available and have gene-
rated renewed hope of combatting this devastating disease. It 
is expected that the results of these recent studies will allow 
for the formal approval of all of these therapies for NMOSD 
in the near future. 
Eculizumab
Eculizumab is a humanised monoclonal antibody which 
inhibits the terminal complement protein C5 and prevents its 
cleavage into C5a and C5b fragments [31]. Preclinical data 
indicates that AQP4 Ab triggers the complement cascade [32], 
which leads to inflammation and the formation of a membrane 
attack complex. The membrane attack complex is implicated 
in astrocyte destruction and neuronal injury. C5a expresses 
proinflammatory activity, and C5b induces the formation of 
a membrane attack complex. Experimental studies have shown 
that complement inhibitor efficiently suppresses NMOSD 
development [33]. Eculizumab has been approved in the USA 
and Europe for paroxysmal nocturnal haemoglobinuria, aty-
pical haemolytic uraemic syndrome, and myasthenia gravis.
In recently published results of a phase 3, randomised, 
double-blind, placebo-controlled, time-to-event trial (PRE-
VENT) it was shown that eculizumab significantly suppres-
sed disease activity in 143 AQP4-Ab-positive patients with 
a moderate to severe course of the disease [34]. Patients were 
randomised 2:1 to either treatment with eculizumab or a pla-
cebo. The drug was administered intravenously at a dose of 
900 mg weekly for the first four doses; subsequently patients 
received a maintenance regimen of 1,200 mg every two weeks 
until relapse or until the end of the trial. Immunosuppressive 
treatment used prior to study entry was allowed (with the 
exception of rituximab) and the group of immunosuppressi-
ve concomitant treatment was 108 patients out of the total 
group of 143. The primary efficacy endpoint was the first 
adjudicated relapse. The primary endpoint occurred much 
less often in the eculizumab group (3 of 96 patients – 3%) 
than in the placebo group (20 of 47 – 43%) (HR, 0.06; 95% 
CI, 0.02 to 0.20; p < 0.001). At 48 weeks, 97.9% of patients 
receiving eculizumab were relapse-free, compared to 63.2% 
of patients receiving the placebo. Symptoms of most of the 
relapses were related to myelitis. Eculizumab was associated 
with a lower adjudicated annualised relapse rate after adjust-
ment than the placebo, which represented the first secondary 
end-point, 0.02 and 0.35, respectively (p < 0.001). No con-
clusions could be made regarding the remaining secondary 
endpoints because the difference between groups for the 
next endpoint in the hierarchy, which was a change in the 
EDSS score, was not significant. The lack of between-group 
differences in disability progression resulted from the trial 
design precluding follow-up beyond six weeks after a single 
relapse. This implied that there were no benefits of the drug 
on disability progression during the short period of the trial. 
Patients from the eculizumab group had higher rates of upper 
respiratory tract infection and headache than did patients in 
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the placebo group: 31 versus 19 events of upper respiratory 
tract infection per 100 patient-years, and 55 versus 38 hea-
dache events per 100 patient-years. One patient in the ecu-
lizumab group who was receiving concomitant azathioprine 
died from pulmonary empyema. Eculizumab increases the 
risk of meningococcal and encapsulated bacterial infection 
[35], and all patients received meningococcal vaccination 
prior to study entry. No cases of meningococcal infection 
were reported during the trial.
Eculizumab (Soliris) was approved by FDA for NMOSD 
treatment following an expedited six-month priority review 
in June 2019.  EMA approved Eculizumab for treatment of 
AQP4-Ab-positive patients with relapsing course of the disease 
in August 2019.
Tocilizumab
Tocilizumab was the first anti-IL6-R mAb tested in the 
treatment of NMOSD. The rationale for using tocilizumab in 
NMO was related to the potential role of IL-6 in the mecha-
nism of NMOSD [36]. This drug has been already used for the 
treatment of severe rheumatic arthritis patients.
Tocilizumab has been tested in NMOSD in several small 
open label studies and case reports [37, 38]. These small series 
have demonstrated a beneficial effect in NMOSD. In one study 
[39], eight female patients with highly active AQP4-Ab-sero-
positive NMOSD (n = 6) and NMOSD patients (n = 2) whose 
disease had been resistant to previous medications including 
B-cell depletion, were switched to tocilizumab (6–8 mg/
kg of body weight per dose). The patients were followed up 
for 30.9 months after switching to tocilizumab. Two of the 
eight patients received add-on therapy consisting of monthly 
corticosteroid pulses or azathioprine. During tocilizumab 
treatment, the median annualised relapse rate significantly 
decreased from 4.0 in the year before tocilizumab therapy 
to 0.4 (p = 0.008), and the median EDSS score significantly 
decreased, from 7.3 to 5.5 (p = 0.03). Active magnetic reso-
nance imaging lesions were seen in 6/8 patients at tocilizumab 
initiation and in 1/8 patients at the last magnetic resonance 
imaging. Three patients remained relapse-free during tocilizu-
mab treatment. The AQP4-Ab titers (p = 0.02) and pain levels 
(p = 0.02) dropped significantly during tocilizumab treatment. 
Adverse effects included moderate cholesterol elevation in 
6/8 patients, infections in 4/8, deep venous thrombosis in 1/8, 
and neutropenia in 1/8.
Tocilizumab development for NMOSD treatment has 
been delayed since another anti-IL6-R mAb, satralizumab, 
was designed to improve pharmacokinetics of IL6-R binding 
and provide better efficacy (see below). However, at the recent 
ECTRIMS meeting in Stockholm, the results were presented 
of an investigator-initiated study (Tango) in China [40]. This 
was a randomised, open-label, parallel-group study comparing 
tocilizumab with azathioprine. Patients (n = 118) were ran-
domly assigned 1:1 to receive 8 mg/kg intravenous tocilizumab 
monthly or 2–3 mg/kg oral azathioprine daily. Treatment was 
administered in conjunction with a gradual discontinuation 
of the previous treatments, followed by monotherapy for 
12 months; 85% of patients were seropositive for AQP-4. 
The primary endpoint was the time to first relapse. After 
a mean observation period of 48 weeks, the percentages of 
relapse-free patients were 91.5% in the tocilizumab group 
and 67.8% in the azathioprine group (HR = 0.32, 95% CI 
0.14–0.70, p = 0.004). Sustained reduction in disability was 
more likely among patients treated with tocilizumab than 
in patients with azathioprine (HR = 0.34, 95% CI 0.13–0.90, 
p = 0.03). Serum levels of anti-AQP4-ab were reduced sig-
nificantly, by 42% with tocilizumab compared to 15% with 
azathioprine (p = 0.03). In the azathioprine group, there 
was a higher frequency of lymphopenia (46% vs 7%) and 
anaemia (27% vs 41%) than in the tocilizumab group. Du-
ring the Tango study, two patients died (one in each arm): 
in tocilizumab because of a severe recurrence of NMOSD, 
and in azathioprine because of meningoencephalitis. In 
both groups, there was an increased number of patients 
with elevated transaminases (31% and 46%) respectively 
for tocilizumab and azathioprine. 
Satralizumab
Satralizumab is a humanised IgG2 subtype recombinant 
anti-IL6-R monoclonal antibody [41]. IL-6 is a pro-inflam-
matory pleiotropic cytokine produced by a large number of 
cell types, including T and B lymphocytes, monocytes and 
fibroblasts [42]. IL-6 plays a role in several immunopatholo-
gical processes such as T-cell activation, induction of immu-
noglobulin secretion, and enhancing macrophage activity, 
and it has been implicated in the mechanism of NMOSD [43]. 
IL-6 specifically contributes to the development of autoimmu-
nity by promoting the generation of Th17 cell lineage [44]. 
Th17 cells are recognised as the primary T cell sub-population 
contributing to the development of autoimmune conditions. 
IL-6 has been found to be significantly elevated in the serum 
and cerebrospinal fluid of patients with NMOSD; it induces 
AQP4-Ab production by plasmablasts, and thus represents 
a novel therapeutic target for NMOSD. 
The molecule of satralizumab was designed to improve 
pharmacokinetics of anti-IL6-R Ab by applying so-called 
‘antibody recycling technology’ [45]. This technology leads 
to increased dissociation of anti-IL6-R Ab from IL6-R within 
the acidic environment of the endosome, while maintaining 
its binding affinity to IL6-R in plasma.  Thus, in the endosome 
acidic environment, IL6-R Ab after degradation of IL6-R is 
dissociated from this complex and can again bind another IL6-
-R in the plasma, increasing its efficacy of IL6-R elimination.
Satralizumab efficacy in NMOSD was evaluated in 83 pa-
tients in a randomised, double-blind, phase 3 study (SAku-
raSky) [46]. AQP4-positive patients represented 66.3% and 
AQP4-negative patients 33.7%. In this study, satralizumab was 
compared to a placebo as an add-on to baseline treatment with 
a stable dose of immunosuppressive and/or corticosteroids. 
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Subjects were randomised to satralizumab (120 mg s.c.) or 
placebo administered at weeks 0, 2, 4, and Q4W thereafter. The 
primary endpoint was time to first protocol-defined relapse 
(PDR), adjudicated by a clinical endpoint committee. Pre-
-specified subgroup analyses included assessing the response 
to treatment by AQP4-Ab serostatus, baseline treatment, and 
region. Satralizumab showed a 79% risk reduction of PDR 
compared to placebo in the NMOSD AQP4-Ab positive sub-
group (HR, 0.21; 95% CI, 0.06-–0.75). At weeks 48 and 96, 
the percentages of relapse-free patients were 91.5% (95% CI, 
69.6%–97.8%) and 91.5% (95% CI, 69.6%–97.8%) with satra-
lizumab and 59.9% (95% CI, 36.3%–77.3%) and 53.3% (95% 
CI, 29.3%–72.4%) with placebo, respectively. However for the 
NMOSD AQP4-Ab negative patients, satralizumab showed 
a risk reduction of PDR that was significantly lower compared 
to the AQP4 Ab positive group, 34% compared to the placebo 
group (HR, 0.66; 95% CI, 0.20–2.23), and the percentages of 
relapse-free patients at weeks 48 and 96 were 84.4% (95% CI, 
50.4%–95.9%) and 56.3% (95% CI, 24.2%–79.2%) with satra-
lizumab, and 75.5% (95% CI, 41.6%–91.4%) and 67.1% (95% 
CI, 34.2%–86.2%) with placebo, respectively. 
More recently, results have become available for satralizu-
mab monotherapy in NMOSD. In the SAkuraStar study, the 
efficacy and safety of satralizumab was compared to placebo 
for relapse prevention in patients with NMOSD [47]. In this 
phase 3, double-blind, placebo-controlled study, 95 patients 
were randomised 2:1 to satralizumab (120 mg s.c.) or placebo, 
administered at weeks 0, 2, 4 and every four weeks thereafter. 
Unlike the SAkuraSky study, concomitant immunosuppressant 
medications were prohibited. Patients with AQP-4 antibodies 
represented 65.1% in the satralizumab group and 71.9% in the 
placebo group. All patients had had ≥ 1 documented relapse, 
including first attack, in the year prior to screening. The prima-
ry endpoint was time to first protocol-defined relapse (PDR) 
adjudicated by a clinical endpoint committee. Satralizumab 
monotherapy significantly reduced the risk of PDR by 55% 
compared to placebo (HR 0.45; 95% CI 0.23–0.89; p = 0.018). 
The percentages of relapse-free patients at week 48 were 76.1% 
in the satralizumab group, and 61.9% in the placebo group. 
At week 96, these values were 72.1% and 51.2%, respectively. 
As in the SAkuraSky study, in the group of patients without 
AQP-4 Ab, satralizumab showed significantly less effect on the 
proportion of relapse-free compared to the AQP-4 Ab positive 
patients, and the difference between satralizumab and placebo 
was not significant.  Satralizumab was well tolerated, and si-
milar proportions of patients in the satralizumab and placebo 
groups experienced adverse events. Rates of serious infections 
were similar between groups. No deaths or anaphylactic rea-
ctions were observed with satralizumab or placebo treatment. 
The clear difference in satralizumab efficacy between 
AQP4 Ab-positive patients and AQP4 Ab-negative patients 
observed in the SAkuraSky and SAkuraStar studies will require 
further analysis. 
Inebilizumab
Inebilizumab is a humanised mAb of IgG1 subtype direc-
ted against the extracellular B cell marker CD19 leading to 
depletion of a broad range of B cells, including autoantibody-
-secreting plasmablasts and CD19-expressing plasma cells 
[48]. Inebilizumab induces a cytotoxic T-lymphocyte response 
and a strong antibody dependent cell cytotoxicity (ADCC) 
against B cells. 
Inebilizumab was evaluated in a phase 3, double-blind, 
randomised, placebo-controlled trial (N-MOmentum) in 
231 NMOSD patients, both AQP4 Ab-positive (91%) and 
AQP4 Ab-negative (9%) [49]. Enrollment of AQP4 Ab-nega-
tive patients required approval of an eligibility committee that 
confirmed the entry criteria. Participants were randomised 
3:1 to either treatment with inebilizumab, 600 mg iv in two 
doses of 300 mg each two weeks apart, or a placebo, with no 
further doses occurring after day 15. Concurrent treatment 
with other immune suppressants was prohibited. 
This means that inebilizumab was the first monotherapy 
tested in NMOSD free from the confounding influence of 
other background immunosuppressive treatments. B cells 
were depleted within approximately four weeks of treatment 
initiation, and this depletion was sustained throughout the 
randomised, controlled period of the study. The patients were 
followed for 28 weeks, after which time the blinded control 
period was stopped early for efficacy. The primary outcome 
measure was time to first adjudicated relapse. Following the 
blinded period, patients were given the option of entering an 
open-label extension period, in which they received 300 mg 
of inebilizumab every six months. Inebilizumab met the 
primary efficacy endpoint with a 77% reduction in the risk 
of developing an NMOSD relapse when compared to placebo 
in AQP4-Ab seropositive patients after 28 weeks of treatment 
(HR: 0.227; p < 0.0001). 
A similar effect on relapse risk (73% reduction) was ob-
served in the total inebilizumab-treated patient population, 
inclusive of AQP4-Ab seronegative patients, (HR: 0.272; 
p < 0.0001). At 28 weeks, at the end of the randomised-
-controlled period, 89% of AQP4-Ab seropositive patients 
treated with inebilizumab were relapse-free, versus 58% in 
the placebo group. Inebilizumab had also met most of the 
secondary endpoints. Reduction of disability worsening 
measured with EDSS in the inebilizumab-treated patients 
was significantly lower, 15.5%, than in the placebo group 
where it was 33.9%, (p = 0.0049). In inebilizumab-treated 
patients, the reduction in NMOSD-related hospitalisations 
was significantly lower, 5.7% of patients, versus placebo 
14.3% (p = 0.01). In this study, MRI was also used as a se-
condary endpoint and showed a reduction in the frequency 
of cumulative total active MRI lesions in inebilizumab-
-treated patients (45.4% patients) versus placebo (57.1 %) 
(p = 0.0034). Visual acuity, another secondary endpoint, 
did not demonstrate a statistically significant difference 
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between inebilizumab-treated patients and placebo. Ine-
bilizumab demonstrated favourable safety and tolerability 
profiles, with an adverse event rate similar to that of the 
placebo. The rate of infusion-related reactions was low in 
both arms. The rates of serious and/or ≥ Grade 3 severity 
adverse events were similar in the inebilizumab (10.3%) 
and placebo (14.3%) groups. Two deaths occurred in the 
open-label period: one related to a severe NMOSD relapse, 
and the other related to a brain event of unclear aetiology 
without a definite diagnosis.
Based on data from the pivotal N-MOmentum study, the 
FDA has granted Breakthrough Therapy Designation (BTD) 
for the development of inebilizumab for the treatment of 
NMOSD. 
Breakthrough Therapy Designation is designed to expedite 
the development and regulatory review of medicines intended 
to treat a serious condition that have shown encouraging 
early clinical results which may demonstrate substantial im-
provement on a clinically significant endpoint over available 
medicines. 
Future perspectives
The pathogenic role of AQP4-Ab in NMOSD is as-
sociated with the production of AQP4-Ab by peripheral 
plasma cells, which can enter the CNS and bind to AQP4 on 
perivascular astrocytes. This binding initiates activation 
of the terminal complement complex and the induction of 
inflammatory lesion formation. Impaired blood-brain bar-
rier function allows for a massive influx of neutrophils and 
eosinophils into the CNS of NMOSD patients. Neutrophil 
counts are elevated in CSF in about 60% of NMOSD pa-
tients during relapse, and about 20% during remission [50]. 
Eosinophils are also present in the CSF of NMOSD patients. 
Degranulation of these cells and the release of several toxic 
proteins and enzymes provide a direct mechanism of da-
mage to astrocytes, followed by oligodendrocyte injury and 
neuronal death [51]. 
Future NMOSD therapies will need to address the inhibi-
tion of AQP4-Ab and prevention of neutrophils and eosinop-
hils activation leading to CNS infiltration.
In vitro and in vivo studies have demonstrated that AQP4-
-Ab deglycosylation or cleavage reduce the complement-
-dependent cytotoxicity and the antibody-dependent cell-
-mediated cytotoxicity, leading to decreased astrocyte damage 
and reduced development of inflammation [52]. Similarly, IgG-
-degrading enzyme produced by Streptococcus pyogenes efficien-
tly cleaved AQP4-Ab in mice in vivo and greatly reduced lesion 
formation in an experimental mice model of NMOSD [53]. The 
bacteria-derived endoglycosidases may target AQP4-Ab and 
reduce its pathogenicity by inhibition of the AQP4-Ab binding 
to AQP4 and preventing NMOSD pathology. Another strategy 
to inhibit interaction between AQP4-Ab with AQP-4 protein 
involved Aquaporumab which is a synthetic IgG that competes 
with AQP4-Ab for AQP 4 binding [54]. In contrast to patho-
genic AQP4-Ab, the mutated Fcγ portion of Aquaporumab 
does not activate the antibody-dependent complement and 
cell-dependent mediated cytotoxicity. Its competitive inhibi-
tion of AQP4-Ab binding depends also on the greater affinity 
of aquaporumab to the AQP4 protein, compared to that of 
pathological AQP4-Ab. Its efficacy to compete with AQP4-Ab 
binding has already been proven in a preclinical study [55].
The dominant presence of neutrophils in inflammatory 
infiltrates of the CNS, and the proven role of these cells in 
NMOSD lesions formation, points at their inhibition as a new 
strategy of NMOSD treatment. 
This concept was supported by findings that intracerebral 
injection of AQP-4 Ab in neutropenic mice induced less 
inflammation and demyelination than in mice with normal 
neutrophil counts [56]. The potential utility of neutrophil 
protease inhibitors might have particular significance in this 
regard [57]. It has already been shown that Sivelestat, an inhi-
bitor of neutrophil elastase, demonstrated a beneficial effect in 
animal models of NMOSD, as evidenced by reduced NMOSD 
lesion formation [56]. Sivelestat was applied intraperitoneally 
or intracerebrally either alone or in combination with cat-
hepsin G inhibitor. In addition to its inhibition of proteolytic 
activity, Sivelestat also reduced the production of inflamma-
tory cytokines and suppressed neutrophil-induced capillary 
permeability and leukocyte kinetics in other conditions [58].
 Eosinophil infiltration is another prominent feature 
of NMOSD lesions, and eosinophils have been found to be 
elevated in the CSF of NMOSD patients [59]. Accordingly, hy-
poeosinophilic mice showed diminished potential for NMOSD 
development. Eosinophil inhibition, either by anti-IL-5 or 
gene depletion, led to reduced lesion severity in experimental 
models of NMOSD. 
These findings confirm the involvement of eosinophils in 
NMOSD’s pathogenesis, and suggests the therapeutic utility 
of eosinophil-targeted drugs [60]. The inhibition of eosinophil 
degranulation has demonstrated promising results in animal 
models of NMOSD. The histamine H1 receptors antagonists 
have been shown to influence eosinophil activity. Cetirizine, 
a selective antagonist of the H1 receptor, was administered 
orally before and during AQP4-Ab intracerebral injection 
and significantly reduced eosinophil infiltrates and lesion 
formation in mice. These results prompted the testing of 
cetirizine in a pilot, open-label, add-on trial to standard the-
rapy for 16 NMOSD patients. Cetirizine was administered at 
a dose of 10 mg daily. After one year of treatment, ARR was 
reduced fourfold in these patients [61]. Thus, antihistaminic 
drugs affecting eosinophilic function might be beneficial as 
an add-on therapy in NMOSD treatment. 
Another future strategy for NMOSD treatment might 
be associated with an attempt to enhance apoptotic death of 
plasma cells. This strategy might reduce the number of cells 
producing pathogenic AQP4-Ab and demonstrate benefit for 
NMOSD patients. 
324
Neurologia i Neurochirurgia Polska 2019, vol. 53, no. 5
www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Table 2. Results of primary findings for novel NMOSD treatment 
Satralizumab
Tocilizumab                   (SAkuraSky) 
(SakuraStar)
Mechanism of action Anti-C5 Anti-CD19 Anti-IL6-R 
Ab recycling
Anti-IL6-R
Patients, number 143 230 83 
95
118
Status AQP-4 Ab 
– positive 143 212 55 
62
100
– negative 0 18 28 
33
18
Placebo + + + 
+
AZT
Concomitant
Immunosuppression + - + 
-
+/-
Relapse free 96.1% 87.6% 91.5%(AQP+) 91.5%
(96 w) (28 w) 72.1% (AQP+) 
(96 w)
(48 w)
Relapse reduction 93.1% 73% 79% (AQP+) NA
(HR) (0.06) (0.272) 74% (AQP+) 
(0.21)
Disability risk reduction NS 0.371 NA 0.34
(OR) NA
HR — hazard ratio; OR — odds ratio; W — weeks; NS — non significant; NA — not available
Bortezomib is a selective inhibitor of the 26S proteasome 
subunit leading to enhanced cell death. Bortezomib has been 
tested in an open-label study including five NMOSD AQP4-
-Ab-positive patients. All patients were refractory to previous 
therapies, and two of them were resistant to RTX. Four of these 
five patients remained stable or improved within 12 months of
the study. Patients treated with bortezomib had a lower plasma 
cell count and diminished levels of serum AQP4-Ab [62].
Conclusions
Recent years have witnessed unprecedented progress 
in the understanding and treatment of NMOSD (Tab. 2). 
2019 has been called the Year of NMOSD. The discovery of the 
pathogenic role of AQP4-Ab and anti-MOG Ab has allowed 
the targeting of the basic immune mechanism of this disease. 
The exciting findings of the recent randomised and con-
trolled trials have provided a realistic hope that the era of 
unproved therapies in NMOSD will come to the end. 
The findings from studies with novel drugs targeting 
complement activation, interfering with IL6-R activation 
and depleting antibody-producing plasma cells, should soon 
bring about a new and effective treatment of this devastating 
disease. These results are very welcome for NMOSD patients 
who have been relegated to off-label therapies with uncertain 
benefits for many years. The approval of new therapies for 
NMOSD will undoubtedly prove to be another breakthrough 
in modern neurology.
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